IPO hopeful rEVO puts off its plans for a $75M debut

Massachusetts biotech rEVO Biologics is postponing its efforts to go public in a $75 million IPO. The company, formerly called GTC Therapeutics, had planned to spend its haul on developing its lead drug, ATryn, to treat preeclampsia. More

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.